These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 35090250)

  • 41. [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia].
    Cao L; Jiang ZQ; Liu WJ; Sun Q; Zhu Y; Li JY; Qian SX; Hong M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):633-642. PubMed ID: 37356919
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Effect of venetoclax plus chemotherapy on treatment-naive acute myeloid leukemia patients with moderate to poor cytogenetic profiles and the combination's influence on the expression of proteins of the anti-apoptoic family].
    Zhonghua Zhong Liu Za Zhi; 2024 Feb; 46(2):161-167. PubMed ID: 38418191
    [No Abstract]   [Full Text] [Related]  

  • 43. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and
    Wang L; Song J; Xiao X; Li D; Liu T; He X
    J Chemother; 2024 May; 36(3):202-207. PubMed ID: 37599456
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
    Qu Q; Liu L; Zhang Y; Li X; Wu D
    Leuk Res; 2015 Dec; 39(12):1353-9. PubMed ID: 26432074
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study.
    Xin F; Yu YH; Shen XL; Zhang GX
    Hematology; 2024 Dec; 29(1):2350319. PubMed ID: 38748459
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Comparison of Therapeutic Efficacy between Hypomenthylating Agents Combined with Venetoclax and Half Dose Priming Regimen in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia].
    Xu MZ; Qiao M; Sun AN; Wu DP; Xue SL; Zhou HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1631-1636. PubMed ID: 36476881
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study.
    Shi H; Yang F; Cao M; Xu T; Zheng P; Guo Y; Su G; Feng S; Li R; Liu R; Liu H; Ma L; Ke X; Hu K
    Ann Hematol; 2024 Aug; 103(8):2993-3004. PubMed ID: 38662205
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
    Pollyea DA; Pratz K; Letai A; Jonas BA; Wei AH; Pullarkat V; Konopleva M; Thirman MJ; Arellano M; Becker PS; Chyla B; Hong WJ; Jiang Q; Potluri J; DiNardo CD
    Am J Hematol; 2021 Feb; 96(2):208-217. PubMed ID: 33119898
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Efficacy and Survival of Venetoclax Based Regimen in the Treatment of Acute Myeloid Leukemia].
    Kong FC; Qi L; Huang WF; Yu M; Zhou YL; Ji DX; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1676-1683. PubMed ID: 38071045
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
    Liu B; Guo Y; Deng L; Qiao Y; Jian J
    Hematology; 2020 Dec; 25(1):414-423. PubMed ID: 33191860
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
    Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
    Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial.
    Liu Y; Li Y; Zhang R; Yu Z; Jing Y
    Front Immunol; 2023; 14():1269163. PubMed ID: 38054008
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy.
    Acker F; Chromik J; Tiedjen E; Wolf S; Vischedyk JB; Makowka P; Enßle JC; Kouidri K; Sebastian M; Steffen B; Oellerich T; Serve H; Neubauer A; Schäfer JA; Bittenbring JT
    Eur J Haematol; 2024 Nov; 113(5):623-630. PubMed ID: 39023132
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺].
    Jing Y; Zhu CY; Zhang Q; Niu JH; Yang H; Liu SY; Zhu HY; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1245-50. PubMed ID: 25338566
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
    DiNardo CD; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Wei AH; Konopleva M; Döhner H; Letai A; Fenaux P; Koller E; Havelange V; Leber B; Esteve J; Wang J; Pejsa V; Hájek R; Porkka K; Illés Á; Lavie D; Lemoli RM; Yamamoto K; Yoon SS; Jang JH; Yeh SP; Turgut M; Hong WJ; Zhou Y; Potluri J; Pratz KW
    N Engl J Med; 2020 Aug; 383(7):617-629. PubMed ID: 32786187
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
    Li X; Suh HS; Lachaine J; Schuh AC; Pratz K; Betts KA; Song J; Dua A; Bui CN
    Value Health; 2023 Dec; 26(12):1689-1696. PubMed ID: 37741447
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fix low dose venetoclax-azacitidine treatment of unfit acute myeloid leukemia patients.
    Miklos E; Oliver TP; Adam K; Eva K; Balazs K; Eszter K; Anett P; Viktoria GK; Jozsef H; Peter R
    Eur J Haematol; 2024 Aug; 113(2):183-189. PubMed ID: 38644361
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine.
    Winters AC; Minhajuddin M; Stevens BM; Major A; Bosma G; Abbott D; Miltgen N; Yuan J; Treece AL; Siegele BJ; Ewalt MD; Gutman JA; Jordan CT; Pollyea DA
    Haematologica; 2024 Jun; 109(6):1766-1778. PubMed ID: 38105738
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical Efficacy of Decitabine Combined with Modified CAG Regimen for Relapse/Refractory Acute Myeloid Leukemia with AML1-ETO
    Liu Q; Fei XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1334-1338. PubMed ID: 27784352
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Efficacy and safety of dexcitabine combined with HAAG regimen in the treatment of recurrent acute myeloid leukemia].
    Wu XF; Li CC; Li TT; Sun L; Lu J; Ran XH
    Zhonghua Yi Xue Za Zhi; 2023 Apr; 103(13):981-985. PubMed ID: 36990713
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.